Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation, polyethylene glycol...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Antibody Structure and Classes

Antibody Structure and Classes

Antibodies, also known as immunoglobulins, are produced by B cells in response to foreign substances, such as bacteria and viruses. These proteins are critical for recognizing and neutralizing these substances, protecting the body from potential harm.
The basic structure of an antibody consists of four protein chains: two identical heavy chains and two identical light chains. These chains are held together by disulfide bonds and other non-covalent interactions, forming a Y-shaped structure.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Use of logit transformation within statistical analyses of experimental results obtained as proportions: example of method validation experiments and EQA in flow cytometry.

Frontiers in molecular biosciences·2024

Same author

Genomic diversity and transmission dynamics of <i>M. tuberculosis</i> in Africa: a systematic review and meta-analysis.

The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease·2020

Same author

MMP-8 and TIMP-1 are associated to periodontal inflammation in patients with rheumatoid arthritis under methotrexate immunosuppression - First results of a cross-sectional study.

Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi·2017

Same author

Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?

Clinical and experimental immunology·2016

Same author

[Angiogenin, bFGF and VEGF: angiogenic markers in breath condensate of patients with pulmonary hypertension].

Pneumologie (Stuttgart, Germany)·2015

Same author

Review of the prevalence and drug resistance of tuberculosis in prisons: a hidden epidemic.

Epidemiology and infection·2014

Search research articles

Related Experiment Video

Updated: Jul 4, 2026

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

[Monoclonal antibodies. Principles, generation, application, and side effects].

U Sack¹, F Emmrich

¹Institut für Klinische Immunologie und Transfusionsmedizin, Medizinische Fakultät, Universität Leipzig, Johannisallee 30, 04103, Leipzig, Germany. ulrich.sack@medizin.uni-leipzig.de

|July 1, 2008

Summary

Monoclonal antibodies are key in internal medicine for treating chronic and malignant diseases. Advances in biotechnology ensure their safe and effective use, with more therapeutic options on the horizon.

More Related Videos

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

Related Experiment Videos

Last Updated: Jul 4, 2026

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Generation of Murine Monoclonal Antibodies by Hybridoma Technology

Published on: January 2, 2017

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Generation of Discriminative Human Monoclonal Antibodies from Rare Antigen-specific B Cells Circulating in Blood

Published on: February 6, 2018

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Generation of Recombinant Human IgG Monoclonal Antibodies from Immortalized Sorted B Cells

Published on: June 5, 2015

Area of Science:

Biotechnology
Immunology
Internal Medicine

Context:

Monoclonal antibodies (mAbs) are increasingly vital in internal medicine.
Their application targets cell surface receptors and cytokines for specific therapies.
This is particularly relevant for chronic and malignant diseases.

Purpose:

To highlight the growing importance and application of monoclonal antibodies in medicine.
To discuss the biotechnological production processes of antibody preparations.
To underscore the safety and future potential of these therapeutic agents.

Summary:

Monoclonal antibodies are integral to modern internal medicine, enabling targeted therapies for complex diseases.
Biotechnological advancements facilitate the production of these antibodies, maintaining specificity.
Despite complex antigen structures, severe side effects are rare, especially with humanized antibodies.

Impact:

Monoclonal antibody therapies offer precise treatment options for chronic and malignant conditions.
The continued development of these antibodies promises expanded diagnostic and therapeutic capabilities.
Enhanced safety profiles of humanized antibodies improve patient outcomes and treatment accessibility.